[MUSIC].
Hello everyone, in this presentation I'm going to be talking about global health
research development and innovation policies.
But firstly, I'd like to talk about some key issues in terms of global health
research development innovation, which I'll refer to as RDI.
So there are often gaps in drugs, vaccine, and technological development for
the health needs of poor and neglected countries.
And this partly explains the health differences,
the gaps between richer and poorer countries.
There are many neglected diseases when it comes to RDI,
and we already discussed a little bit about this in week two.
Medical and technological R&D is actually very important part of market economies.
But markets are not driven to meet the issues of neglected diseases.
So currently, R&D funding for neglected diseases is
largely provided by the public sector, around 64% by the public sector.
Otherwise, by philanthropic and pharmaceutical industry.
However, more recently there's been more private industry funding,
that's increased more actually.
Research and development for drugs is quite expensive and
the resulting products can also be expensive, hence a problem for
poorer countries, lower middle income countries.
So our question has been, how do we delink the costs
of RDI from the products that it's produced?
Other issue include the monitoring and evaluation of global health problems.
And for example, some countries don't have civil registration or
information on births and deaths.
So globally, around two-thirds of deaths,
or 38 million deaths, actually go unregistered.
So there's a lot of scope for development in terms of data and research and systems.
A couple of years ago there was a global strategy and
plan of action on public health innovation and intellectual property developed.
And there was a WHO consultative expert working group set up, or
CEWG, as it's referred to.
And they had a mandate to consider who we improve access to medicines and
technologies through RDI.
So their four key tasks were to develop a report on coordinating activity for
RDI and funds for RDI.
Separating the costs of medicines and technologies from the products of RDI.